It may seem odd, as unprecedented public/private sector R&D alliances work to discover and develop therapies to counter COVID-19, that some are trying to punish the companies trying to get us out of this mess. For example, House “Progressive” leaders unveiled the “three protections” they will try to insert in the next Congressional aid package, beginning with this: “NO EXCLUSIVITY: Pharmaceutical manufacturers should not be granted exclusivity for any COVID-19 vaccine, drug, or other therapeutic-whether it has been developed with U.S. taxpayer dollars and publicly funded, or not.” Consider the last phrase. They would take away rights to technologies developed entirely with private funding without evidence of any public need for doing so.
Patent
- Enablement
- Fee Shifting
- Litigation
- Game On: How IP Helps the Video Game Industry Level Up
- CAFC Affirms District Court Section 101 Dismissal in Patent Infringement Suit Brought Against Samsung/Apple; Newman Dissents
- CAFC Remands Walker Process Antitrust Issue to Fifth Circuit under Xitronex I Precedent
- Geltor is seeking a Senior Patent Agent
- Other Barks & Bites for Friday, June 11: EU Parliament Calls for TRIPS Patent Waiver, Innovation and Competition Act Passes Senate, and Foreign Lawyers Can Now Sit for China’s Patent Bar
Recent Posts
- Game On: How IP Helps the Video Game Industry Level Up
- CAFC Affirms District Court Section 101 Dismissal in Patent Infringement Suit Brought Against Samsung/Apple; Newman Dissents
- CAFC Remands Walker Process Antitrust Issue to Fifth Circuit under Xitronex I Precedent
- Geltor is seeking a Senior Patent Agent
- Other Barks & Bites for Friday, June 11: EU Parliament Calls for TRIPS Patent Waiver, Innovation and Competition Act Passes Senate, and Foreign Lawyers Can Now Sit for China’s Patent Bar